Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Benzodiazepine or Empathogen or [[:Category:TNF_inhibitors|TNF-α inhibitor]]

Use the filters below to narrow your results.

generic:
brand:
None (25) · Dalmane (1) · Doral (1) · Halcion (1) · Humira; biosimilars Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Yusimry, Abrilada (1) · Lexotan (1) · Librium (1) · Mogadon (1) · Onfi (1) · ProSom (1) · Restoril (1) · Rohypnol (1) · Serax (1) · Tranxene (1) · Versed (1) · Xanax (1)
classes: (Click arrow to add another value)
mechanism:
Extremely potent GABAA positive allosteric modulator (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · GABAA positive allosteric modulator (18) · GABAA positive allosteric modulator; low sedation (1) · GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) · GABAA positive allosteric modulator; very long half-life (1) · MAO inhibitor; monoamine releasing agent (1) · MAO inhibitor; serotonin releasing agent (1) · Monoamine releasing agent (3) · Monoamine releasing agent; 5-HT2A agonist (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Serotonin releasing agent (2) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Serotonin/norepinephrine/dopamine releasing agent (3) · '"`UNIQ--vote-000010F8-QINU`"' Pre-treatment screening for latent TB (PPD or IGRA) and chronic hepatitis B is standard. Anti-drug antibody formation is a recognized cause of secondary loss of response'"`UNIQ--ref-000010F9-QINU`"'. (1)
uses:
None (39) · '"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1)
starting dose:
None (38) · 0.25 mg (1) · 40 mg SC every other week (most adult indications); IBD induction 160 mg week 0, 80 mg week 2, then 40 mg every other week (1)
preparations:
None (38) · 0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 40 mg/0.4 mL or 40 mg/0.8 mL prefilled syringe and autoinjector pen; 10, 20, 80 mg pediatric/induction strengths (1)
fda max:
None (38) · 10 mg/d (1) · 40 mg every week (selected indications); otherwise 40 mg every other week (1)
routes:
None (38) · Oral (1) · Subcutaneous (1)
onset:
None (38) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · Symptomatic effect within weeks; full response by 12-24 weeks (1)
duration:
None (38) · 2 weeks per dose (1) · 6 h (immediate-release); ~11 h (extended-release) (1)
halflife:
None (38) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · ~14 days'"`UNIQ--ref-00001103-QINU`"' (1)
bioavailability:
None (38) · 80-90% oral (1) · ~64% from SC depot'"`UNIQ--ref-00001104-QINU`"' (1)
pregnancy:
None (39) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1)
legal:
None (39) · Schedule IV (US) (1)

Showing below up to 40 results in range #1 to #40.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"